James George Robinson Acquires 15,000 Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Director James George Robinson purchased 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The shares were bought at an average price of $3.72 per share, with a total value of $55,800.00. Following the purchase, the director now owns 3,062,550 shares in the company, valued at $11,392,686. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

James George Robinson also recently made the following trade(s):

  • On Wednesday, August 2nd, James George Robinson acquired 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.79 per share, with a total value of $18,950.00.
  • On Thursday, August 3rd, James George Robinson acquired 10,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.73 per share, with a total value of $37,300.00.
  • On Thursday, July 6th, James George Robinson acquired 3,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.92 per share, with a total value of $11,760.00.
  • On Wednesday, July 5th, James George Robinson acquired 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average cost of $3.97 per share, with a total value of $19,850.00.
  • On Friday, July 7th, James George Robinson purchased 11,500 shares of Nymox Pharmaceutical Corporation stock. The stock was purchased at an average cost of $4.00 per share, with a total value of $46,000.00.
  • On Wednesday, June 28th, James George Robinson acquired 8,500 shares of Nymox Pharmaceutical Corporation stock. The shares were bought at an average cost of $4.09 per share, with a total value of $34,765.00.
  • On Monday, June 26th, James George Robinson acquired 15,000 shares of Nymox Pharmaceutical Corporation stock. The shares were bought at an average cost of $3.80 per share, with a total value of $57,000.00.
  • On Tuesday, June 20th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.76 per share, for a total transaction of $18,800.00.
  • On Monday, June 19th, James George Robinson bought 5,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.79 per share, for a total transaction of $18,950.00.
  • On Wednesday, June 21st, James George Robinson bought 15,000 shares of Nymox Pharmaceutical Corporation stock. The stock was acquired at an average price of $3.77 per share, for a total transaction of $56,550.00.

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) traded up 0.87% during trading on Friday, hitting $3.49. 96,673 shares of the company’s stock were exchanged. The company’s market cap is $182.76 million. The firm has a 50 day moving average price of $3.84 and a 200 day moving average price of $3.83. Nymox Pharmaceutical Corporation has a 52-week low of $2.31 and a 52-week high of $5.79.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Rincon Hill News and is owned by of Rincon Hill News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://rinconhillneighbors.org/2017/08/19/nymox-pharmaceutical-corporation-nasdaqnymx-director-james-george-robinson-acquires-15000-shares-updated-updated.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in Nymox Pharmaceutical Corporation during the second quarter worth approximately $117,000. Rhumbline Advisers purchased a new stake in Nymox Pharmaceutical Corporation during the second quarter worth $134,000. Northern Trust Corp purchased a new stake in Nymox Pharmaceutical Corporation during the second quarter worth $199,000. Teachers Advisors LLC purchased a new stake in Nymox Pharmaceutical Corporation during the second quarter worth $218,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in Nymox Pharmaceutical Corporation during the second quarter worth $222,000. 2.25% of the stock is currently owned by institutional investors and hedge funds.

Separately, ValuEngine cut shares of Nymox Pharmaceutical Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, June 27th.

About Nymox Pharmaceutical Corporation

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Insider Buying and Selling by Quarter for Nymox Pharmaceutical Corporation (NASDAQ:NYMX)

Receive News & Ratings for Nymox Pharmaceutical Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical Corporation and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.